The Ontario Genomics Institute is entering a partnership with Amorfix Life Sciences Inc. to develop the first effective blood test for alzheimers. The deal is structured as follows:

Pursuant to a term sheet executed December 22, 2005, OGI has executed a subscription agreement to
invest $100,000 in Amorfix to accelerate the EP-ADTM project. OGI will, upon closing, invest $50,000
receiving 100,000 common shares of AMF and 50,000 warrants to purchase shares for $.90 for a term of
two years. Upon the achievement of a defined research milestone, OGI will invest $50,000 at market
price and receive a one-half warrant for each share purchased to purchase a share at the then market price
within 2 years. This transaction is subject to acceptance for filing by the TSX Venture exchange.